ctDNA to help treat oligometastatic cancer with local ablation

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective observational study that looks at ctDNA levels before, during, and after local ablative therapy for oligometastatic solid tumors. Researchers will collect serial blood samples and use archival tumor tissue to analyze ctDNA and total cfDNA, aiming to see how ctDNA relates to residual disease, recurrence, and survival. The goal is to determine ctDNA detection rates, how ctDNA changes after treatment, and whether it can serve as a prognostic and response biomarker across tumor types and LAT modalities.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Metastatic spread from histopathological diagnosed solid cancer
* Planned for LAT (local ablative therapy) for OMD (oligometastatic disease)
* ≥ 18 years
* Written and oral consent

Exclusion Criteria:

* Other cancer disease within 5 years
* Conditions that will contraindicate blood samples

Where it's running

• Department of Oncology, Aarhus University Hospital
  Aarhus N, Denmark Recruiting

Study contacts

• Study coordinator: Louise B Callesen, MD, PhD
• Email: Louicall@rm.dk
• Phone: 30482884

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Prostate Radiotherapy and Metastasis-Directed Therapy in Synchronous Oligometastatic Prostate Cancer

  This registry follows men with new, limited metastatic prostate cancer who receive targeted radiotherapy to the prostate and all visible metastases to see how they do over time in real-world care.

  Recruiting Affidea Nu-med Center of Oncological DIagnostics and Therapy · Zamość, Lublin Voivodeship · NCT07686016

• Comprehensive radiotherapy to all metastases plus primary prostate radiotherapy versus prostate-only radiotherapy for men with oligometastatic prostate cancer

  This tests whether adding radiation to all PSMA-PET-visible metastases along with standard systemic therapy helps men with newly diagnosed oligometastatic prostate cancer stay progression-free longer than treating the prostate alone.

  Recruiting Peking University First Hospital · Beijing, Beijing Municipality and 2 other locations · NCT07015138

• Maximal tumor eradication for patients with oligometastatic prostate cancer

  This study is testing a new combination treatment for men with oligometastatic prostate cancer to see if it can improve their survival and quality of life.

  Recruiting Phase 2/3 RenJi Hospital · Shanghai · NCT06972511

• Genomic biomarker-guided therapy for advanced prostate cancer

  This study is testing if personalized treatment based on genetic markers can help men with advanced prostate cancer before surgery.

  Recruiting Phase 2 The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT06387056

• Combining immune therapy and radiation for prostate cancer treatment

  This study is testing a new treatment that combines immune therapy drugs with targeted radiation to see if it helps men with a specific type of prostate cancer live longer and feel better.

  Recruiting Phase 2 Columbia University · New York, New York · NCT05915442

• Using Lu-PSMA with SABR for treating oligometastatic prostate cancer

  This study is testing whether adding a special targeted therapy called Lu-PSMA to radiation treatment can help people with a few spots of prostate cancer live longer without their cancer getting worse.

  Recruiting at 4 sites Phase 2 Peter MacCallum Cancer Centre, Australia · St Leonards, New South Wales and 3 other locations · NCT05560659

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.